Murine intracerebral interleukin-2 injection: pathological and immunological effects

Area of Science:

• Neuroimmunology
• Immunotherapy
• Recombinant protein applications

Background:

• Interleukin-2 (IL-2) plays a crucial role in immune responses.
• The potential therapeutic use of IL-2 in brain tumors necessitates understanding its effects on the central nervous system.
• Investigating direct toxicity and immune responses to intracerebral IL-2 is vital for safe clinical application.

Purpose of the Study:

• To evaluate pathological changes in normal brain tissue after intracerebral recombinant IL-2 (rIL-2) administration.
• To assess the induction of antibodies against IL-2 following intracerebral rIL-2 infusion.
• To determine the effect of intracerebral rIL-2 on interleukin-2 receptor (IL-2R) expression in the brain.

Main Methods:

• Recombinant IL-2 was administered intracerebrally to C57BL/6 mice in varying doses and frequencies.
• Sham control experiments used purified mouse albumin.
• Histological analysis, enzyme-linked immunosorbent assay (ELISA) for anti-IL-2 antibodies and IL-2 activity, and immunofluorescence for IL-2R expression were performed.

Main Results:

• No significant histological differences were observed between rIL-2 treated and sham control groups, indicating no direct brain toxicity.
• Low levels of anti-IL-2 antibodies were detected only in mice receiving repeated high doses; other groups showed insignificant levels.
• Serum IL-2 activity remained low, and IL-2R expression in the brain was not enhanced up to 8 weeks post-infusion.

Conclusions:

• Direct intracerebral administration of rIL-2 does not appear to induce significant pathological changes or a robust immune response in normal brain tissue.
• The lack of enhanced IL-2R expression suggests that the brain's intrinsic response to IL-2 is minimal under these conditions.
• These findings support the potential safety of using direct intracerebral rIL-2 infusion as a strategy for brain tumor immunotherapy.